New Horizon Raises $20 Million For Diagnostics In Qiming-Led B Round
Published: Aug 10, 2017
New Horizon Health, a Beijing-Hangzhou company developing early-stage cancer screening products, raised $20 million in a B round led by Qiming Venture Partners. New Horizon's first product is a home-based test for colorectal cancer using fecal gene analysis (FIT-DNA) technology. Horizon believes the test can detect precancerous lesions five years earlier than blood tests. Using a colonoscopy, the lesions can be removed before they become cancerous. Previous investors Legend Capital and SoftBank China also participated in the B round.